Shuttle Pharmaceuticals Expands Trial
This is a news story, published by MSN, that relates primarily to Shuttle Pharmaceuticals Holdings news.
drug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsMSN news
For more news from MSN, you can click here:
more news from MSNAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
glioblastoma treatment. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Shuttle Pharmaceuticals news, Shuttle Pharmaceuticals Holdings news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
RopidoxuridineInvesting.com
•Health
Health
Shuttle Pharmaceuticals expands glioblastoma trial
86% Informative
Shuttle Pharmaceuticals Holdings , Inc. has amended its agreement with Theradex Systems to expand a clinical trial for a potential cancer treatment.
The update includes an increase in the patient count from 15 to 16, to account for the addition of a replacement patient.
The expansion comes as the company reports an EBITDA of -$7.2 million in the last twelve months .
InvestingPro analysis suggests the stock is currently undervalued, though investors should note that the company is burning through cash.
VR Score
88
Informative language
89
Neutral language
62
Article tone
formal
Language
English
Language complexity
75
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
2
Source diversity
1
Affiliate links
no affiliate links
Small business owner?